Maravai Lifesciences price target raised to $9 from $8 at BofA

BofA analyst Michael Ryskin raised the firm’s price target on Maravai Lifesciences to $9 from $8 and keeps a Buy rating on the shares. The company spent much of its earnings call discussing “Maravai 3.0,” which the firm calls “a cleaner version of MRVI than we’ve seen in prior years.” As end-markets stabilize and headwinds fade, this should lead to further acceleration in growth and profitability, the analyst added.